Follow @ebcapital
Recent articles
Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?
Following European approval earlier this month, bluebird bio announced its beta-thalassemia gene therapy will launch with a sky-high price tag.
HEXO: 7 Facts About This Marijuana Stock's Quarterly Results
Surging sales were shy of industry watchers' expectations, but management's guidance shows it's unfazed by a quarterly slowdown.
Global Blood's Sickle Cell Treatment Fails to Impress
Updated data from a late-stage trial of voxelotor fell shy of investors' expectations.
Healthcare Investor Brad Loncar Breaks Down ASCO 2019's Winners and Losers
Here are this year's winners and losers following the Super Bowl of biotech conferences.
3 Top Dividend Stocks to Buy in June
Here's why it could be the perfect time to add these income stocks to your portfolio.
A Biotech Stock to Watch Now
Investors will get additional insight into a potential new treatment for sickle cell disease on Friday.
3 Technology Titans You Can Buy on Sale
These big-cap technology companies could be bargains worth buying.
Why ChemoCentryx Shares Crashed 19.1% Today
Shock waves from a competitor's stumble sent the clinical-stage biotech's shares reeling.
It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy
European regulators have signed off on the biotech's revolutionary gene therapy for beta-thalassemia.
3 Fast-Growing Healthcare Stocks to Buy If the Market Crashes
These top healthcare stocks could be worth adding to portfolios if the market sells off sharply.
Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?
The sky-high price of this revolutionary new gene therapy may not be as crazy as it seems.
Why Soliton's Shares Went on a Roller Coaster Ride Today
The company is riding high following FDA clearance for its tattoo removal medical device.
Charlotte's Web: 5 Facts About Its Latest Quarterly Results
Sales are soaring at this marijuana stock, but rising revenue isn't the only thing you should know about its performance last quarter.
How BioMarin May Revolutionize the Hemophilia Treatment Market
The latest trial results for its hemophilia A gene therapy suggest it may eliminate or significantly reduce the need for weekly infusions.
Why Anaplan Is Skyrocketing 18% Today
Increasing demand for its forecasting software is sending sales soaring.
Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio
A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
2 Top Stocks to Watch at ASCO 2019
These biotech stocks could pop or drop next month following ASCO's annual conference.
Here's Why Arrowhead Pharmaceuticals Skyrocketed 12.7% Today
The clinical-stage developer of RNAi therapies is being added to the S&P 600 index.
Warren Buffett Is the World's Biggest Investor in These 5 Stocks
Berkshire Hathaway is the single largest shareholder of these well-known companies.
Top Stocks Warren Buffett Just Sold
Berkshire Hathaway sold these stocks last quarter, and that could mean you should sell them, too.